Discussing Drug Use With Health Care Providers Is Associated With Perceived Need and Receipt of Drug Treatment Among Adults in the United States: We Need to Talk.


Journal

Medical care
ISSN: 1537-1948
Titre abrégé: Med Care
Pays: United States
ID NLM: 0230027

Informations de publication

Date de publication:
07 2020
Historique:
entrez: 11 6 2020
pubmed: 11 6 2020
medline: 8 8 2020
Statut: ppublish

Résumé

Drug treatment utilization is low despite a high public health burden of drug use disorders (DUDs). Engaging people at risk for DUDs across a broader range of health care settings may improve uptake of drug treatment. To estimate the prevalence of drug use screening/discussions between health care providers and individuals with past-year drug use, and to assess the associations between drug use screening/discussions and perceived need and use of drug treatment. We analyzed representative cross-sectional data from the 2015 to 2017 National Surveys on Drug Use and Health. The sample included adults aged 18 years and above reporting past-year drug use and ≥1 health care visit. We measured correlates of drug use screening/discussions using multinomial logistic regression. Overall and among adults meeting DUD criteria, we used logistic regression to estimate associations between drug use screening/discussions and (1) past-year drug treatment and (2) perceived need for treatment. In the full sample (n=21,505), 34.50% reported no screening/discussions, 44.50% reported screening only, and 21.00% reported discussions with providers. Discussions were associated with significantly higher odds of receiving any drug treatment [adjusted odds ratio (aOR)=3.52 (2.66-4.65)], specialty drug treatment [aOR=4.13 (2.92-5.82)], and perceived treatment need [aOR=2.08 (1.21-3.59)]. Among people with DUD (n=3,834; 15.69%), discussions were associated with treatment use, but not with perceived need. Discussing drug use with providers may impact people's perceptions of drug treatment need and use, indicating potential opportunities to engage people in addiction treatment. Addressing barriers to discussing drug use across care settings could increase treatment use, particularly among people with DUD.

Sections du résumé

BACKGROUND
Drug treatment utilization is low despite a high public health burden of drug use disorders (DUDs). Engaging people at risk for DUDs across a broader range of health care settings may improve uptake of drug treatment.
OBJECTIVES
To estimate the prevalence of drug use screening/discussions between health care providers and individuals with past-year drug use, and to assess the associations between drug use screening/discussions and perceived need and use of drug treatment.
METHODS
We analyzed representative cross-sectional data from the 2015 to 2017 National Surveys on Drug Use and Health. The sample included adults aged 18 years and above reporting past-year drug use and ≥1 health care visit. We measured correlates of drug use screening/discussions using multinomial logistic regression. Overall and among adults meeting DUD criteria, we used logistic regression to estimate associations between drug use screening/discussions and (1) past-year drug treatment and (2) perceived need for treatment.
RESULTS
In the full sample (n=21,505), 34.50% reported no screening/discussions, 44.50% reported screening only, and 21.00% reported discussions with providers. Discussions were associated with significantly higher odds of receiving any drug treatment [adjusted odds ratio (aOR)=3.52 (2.66-4.65)], specialty drug treatment [aOR=4.13 (2.92-5.82)], and perceived treatment need [aOR=2.08 (1.21-3.59)]. Among people with DUD (n=3,834; 15.69%), discussions were associated with treatment use, but not with perceived need.
CONCLUSIONS
Discussing drug use with providers may impact people's perceptions of drug treatment need and use, indicating potential opportunities to engage people in addiction treatment. Addressing barriers to discussing drug use across care settings could increase treatment use, particularly among people with DUD.

Identifiants

pubmed: 32520836
doi: 10.1097/MLR.0000000000001340
pii: 00005650-202007000-00007
pmc: PMC8112806
mid: NIHMS1578393
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

617-624

Subventions

Organisme : NIDA NIH HHS
ID : K01 DA045224
Pays : United States
Organisme : NIDA NIH HHS
ID : L30 DA042436
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA037866
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA031099
Pays : United States

Références

Addiction. 2017 May;112(5):818-827
pubmed: 27886657
Nicotine Tob Res. 2011 Dec;13(12):1193-201
pubmed: 21859810
Epidemiology. 2018 Sep;29(5):e45-e47
pubmed: 29912013
Subst Abus. 2016 Apr-Jun;37(2):336-42
pubmed: 26453188
Public Health Rev. 2017 Dec 29;38:31
pubmed: 29450101
Drug Alcohol Depend. 2014 Dec 1;145:113-20
pubmed: 25456572
J Subst Abuse Treat. 2016 Feb;61:47-59
pubmed: 26531892
Drug Alcohol Depend. 2009 Jan 1;99(1-3):280-95
pubmed: 18929451
Psychiatr Serv. 2017 Jun 1;68(6):542-548
pubmed: 28093059
J Subst Abuse Treat. 2018 Jan;84:30-41
pubmed: 29195591
Lancet Psychiatry. 2018 Dec;5(12):987-1012
pubmed: 30392731
Ann Intern Med. 2017 Aug 15;167(4):268-274
pubmed: 28693043
Drug Alcohol Depend. 2013 Jan 1;127(1-3):59-64
pubmed: 22770461
Milbank Q. 2014 Jun;92(2):289-318
pubmed: 24890249
Am J Prev Med. 2018 Oct;55(4):524-532
pubmed: 30135038
Drug Alcohol Depend. 2013 Jul 1;131(1-2):23-35
pubmed: 23490450
J Subst Abuse Treat. 2017 Apr;75:54-61
pubmed: 28237055
Addiction. 2017 Feb;112 Suppl 2:54-64
pubmed: 28074568
Addict Behav. 2008 Jun;33(6):782-98
pubmed: 18262368
Obstet Gynecol. 2015 Jun;125(6):1529-1537
pubmed: 26000541
Subst Abus. 2015;36(3):281-8
pubmed: 25127073
Womens Health Issues. 2017 May - Jun;27(3):264-270
pubmed: 28129942
J Subst Abuse Treat. 2018 Sep;92:85-90
pubmed: 30032949
JAMA. 2014 Aug 6;312(5):492-501
pubmed: 25096689
J Subst Abuse Treat. 2018 Nov;94:1-8
pubmed: 30243409
Arch Intern Med. 2010 Jul 12;170(13):1155-60
pubmed: 20625025
J Addict Med. 2020 Jan/Feb;14(1):63-68
pubmed: 30946091
Addict Sci Clin Pract. 2018 Apr 9;13(1):8
pubmed: 29628018

Auteurs

Pia M Mauro (PM)

Department of Epidemiology, Columbia University, Mailman School of Public Health, New York, NY.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH